Cargando…
Triple-Gene Therapy for Stroke: A Proof-of-Concept in Vivo Study in Rats
Natural brain repair after stroke is extremely limited, and current therapeutic options are even more scarce with no clinical break-through in sight. Despite restricted regeneration in the central nervous system, we have previously proved that human umbilical cord blood mono-nuclear cells (UCB-MC) t...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818439/ https://www.ncbi.nlm.nih.gov/pubmed/29497380 http://dx.doi.org/10.3389/fphar.2018.00111 |
_version_ | 1783301019052015616 |
---|---|
author | Sokolov, Mikhail E. Bashirov, Farid V. Markosyan, Vage A. Povysheva, Tatyana V. Fadeev, Filip O. Izmailov, Andrey A. Kuztetsov, Maxim S. Safiullov, Zufar Z. Shmarov, Maxim M. Naroditskyi, Boris S. Palotás, András Islamov, Rustem R. |
author_facet | Sokolov, Mikhail E. Bashirov, Farid V. Markosyan, Vage A. Povysheva, Tatyana V. Fadeev, Filip O. Izmailov, Andrey A. Kuztetsov, Maxim S. Safiullov, Zufar Z. Shmarov, Maxim M. Naroditskyi, Boris S. Palotás, András Islamov, Rustem R. |
author_sort | Sokolov, Mikhail E. |
collection | PubMed |
description | Natural brain repair after stroke is extremely limited, and current therapeutic options are even more scarce with no clinical break-through in sight. Despite restricted regeneration in the central nervous system, we have previously proved that human umbilical cord blood mono-nuclear cells (UCB-MC) transduced with adenoviral vectors carrying genes encoding vascular endothelial growth factor (VEGF), glial cell-derived neurotrophic factor (GDNF), and neural cell adhesion molecule (NCAM) successfully rescued neurons in amyotrophic lateral sclerosis and spinal cord injury. This proof-of-principle project was aimed at evaluating the beneficial effects of the same triple-gene approach in stroke. Rats subjected to distal occlusion of the middle cerebral artery were treated intrathecally with a combination of these genes either directly or using our cell-based (UCB-MC) approach. Various techniques and markers were employed to evaluate brain injury and subsequent recovery after treatment. Brain repair was most prominent when therapeutic genes were delivered via adenoviral vector- or UCB-MC-mediated approach. Remodeling of brain cortex in the stroke area was confirmed by reduction of infarct volume and attenuated neural cell death, depletion of astrocytes and microglial cells, and increase in the number of oligodendroglial cells and synaptic proteins expression. These results imply that intrathecal injection of genetically engineered UCB-MC over-expressing therapeutic molecules (VEGF, GDNF, and NCAM) following cerebral blood vessel occlusion might represent a novel avenue for future research into treating stroke. |
format | Online Article Text |
id | pubmed-5818439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58184392018-03-01 Triple-Gene Therapy for Stroke: A Proof-of-Concept in Vivo Study in Rats Sokolov, Mikhail E. Bashirov, Farid V. Markosyan, Vage A. Povysheva, Tatyana V. Fadeev, Filip O. Izmailov, Andrey A. Kuztetsov, Maxim S. Safiullov, Zufar Z. Shmarov, Maxim M. Naroditskyi, Boris S. Palotás, András Islamov, Rustem R. Front Pharmacol Pharmacology Natural brain repair after stroke is extremely limited, and current therapeutic options are even more scarce with no clinical break-through in sight. Despite restricted regeneration in the central nervous system, we have previously proved that human umbilical cord blood mono-nuclear cells (UCB-MC) transduced with adenoviral vectors carrying genes encoding vascular endothelial growth factor (VEGF), glial cell-derived neurotrophic factor (GDNF), and neural cell adhesion molecule (NCAM) successfully rescued neurons in amyotrophic lateral sclerosis and spinal cord injury. This proof-of-principle project was aimed at evaluating the beneficial effects of the same triple-gene approach in stroke. Rats subjected to distal occlusion of the middle cerebral artery were treated intrathecally with a combination of these genes either directly or using our cell-based (UCB-MC) approach. Various techniques and markers were employed to evaluate brain injury and subsequent recovery after treatment. Brain repair was most prominent when therapeutic genes were delivered via adenoviral vector- or UCB-MC-mediated approach. Remodeling of brain cortex in the stroke area was confirmed by reduction of infarct volume and attenuated neural cell death, depletion of astrocytes and microglial cells, and increase in the number of oligodendroglial cells and synaptic proteins expression. These results imply that intrathecal injection of genetically engineered UCB-MC over-expressing therapeutic molecules (VEGF, GDNF, and NCAM) following cerebral blood vessel occlusion might represent a novel avenue for future research into treating stroke. Frontiers Media S.A. 2018-02-15 /pmc/articles/PMC5818439/ /pubmed/29497380 http://dx.doi.org/10.3389/fphar.2018.00111 Text en Copyright © 2018 Sokolov, Bashirov, Markosyan, Povysheva, Fadeev, Izmailov, Kuztetsov, Safiullov, Shmarov, Naroditskyi, Palotás and Islamov. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Sokolov, Mikhail E. Bashirov, Farid V. Markosyan, Vage A. Povysheva, Tatyana V. Fadeev, Filip O. Izmailov, Andrey A. Kuztetsov, Maxim S. Safiullov, Zufar Z. Shmarov, Maxim M. Naroditskyi, Boris S. Palotás, András Islamov, Rustem R. Triple-Gene Therapy for Stroke: A Proof-of-Concept in Vivo Study in Rats |
title | Triple-Gene Therapy for Stroke: A Proof-of-Concept in Vivo Study in Rats |
title_full | Triple-Gene Therapy for Stroke: A Proof-of-Concept in Vivo Study in Rats |
title_fullStr | Triple-Gene Therapy for Stroke: A Proof-of-Concept in Vivo Study in Rats |
title_full_unstemmed | Triple-Gene Therapy for Stroke: A Proof-of-Concept in Vivo Study in Rats |
title_short | Triple-Gene Therapy for Stroke: A Proof-of-Concept in Vivo Study in Rats |
title_sort | triple-gene therapy for stroke: a proof-of-concept in vivo study in rats |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818439/ https://www.ncbi.nlm.nih.gov/pubmed/29497380 http://dx.doi.org/10.3389/fphar.2018.00111 |
work_keys_str_mv | AT sokolovmikhaile triplegenetherapyforstrokeaproofofconceptinvivostudyinrats AT bashirovfaridv triplegenetherapyforstrokeaproofofconceptinvivostudyinrats AT markosyanvagea triplegenetherapyforstrokeaproofofconceptinvivostudyinrats AT povyshevatatyanav triplegenetherapyforstrokeaproofofconceptinvivostudyinrats AT fadeevfilipo triplegenetherapyforstrokeaproofofconceptinvivostudyinrats AT izmailovandreya triplegenetherapyforstrokeaproofofconceptinvivostudyinrats AT kuztetsovmaxims triplegenetherapyforstrokeaproofofconceptinvivostudyinrats AT safiullovzufarz triplegenetherapyforstrokeaproofofconceptinvivostudyinrats AT shmarovmaximm triplegenetherapyforstrokeaproofofconceptinvivostudyinrats AT naroditskyiboriss triplegenetherapyforstrokeaproofofconceptinvivostudyinrats AT palotasandras triplegenetherapyforstrokeaproofofconceptinvivostudyinrats AT islamovrustemr triplegenetherapyforstrokeaproofofconceptinvivostudyinrats |